title: [Cutaneous side effects of EGFR inhibitors--appearance and management].
abstract: Epidermal growth factor receptor (EGFR) inhibitors such as cetuximab, erlotinib, panitumumab und gefitinib, are increasingly used for the treatment of advanced, metastatic, or recurrent tumours like colorectal carcinoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN) and pancreatic cancer. For this reason the treatment of common cutaneous side effects of EGFR inhibitors has become important: they stigmatize the patient in daily life and may lead to efficacious therapie being discontinued. Depending on the particular EGFR inhibitor, an acneiform rash occurs in 30 to 90 % of patients. Severity, site, stage of eruptions and individual response influence the decision of treatment in the given case. It follows the forms of treatment for acne and rosacea, including topical and systemic antibiotics for their antimicrobial effect and anti-inflammatory effect, sometimes in combination with topical steroids. After several weeks additional sebostatic skin reactions, paronychia and changes in the hair structure may occur, calling for individualized treatment. Only multidisciplinary collaboration between oncologists, radiotherapist and dermatologists may provide an optimal patient care. This article gives an overview of the occurrence and latest treatment options of the cutaneous side effects caused by treatment with EGFR inhibitors.
authors.affiliation: Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians Universität München. wollenberg@lrz.uni-muenchen.de
authors.forename: A
authors.initials: A
authors.lastname: Wollenberg
authors.forename: J
authors.initials: J
authors.lastname: Kroth
authors.forename: A
authors.initials: A
authors.lastname: Hauschild
authors.forename: T
authors.initials: T
authors.lastname: Dirschka
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D003875:Drug Eruptions / Q000175:diagnosis* / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006201:Hair Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D052016:Mucositis / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy*; D000077544:Panitumumab; D010304:Paronychia / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib